SEC Form 4

FORM 4		UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5
	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* KAKKIS EMIL D (Last) (First) (Middle) C/O ULTRAGENYX PHARMACEUTICAL INC. 60 LEVERONI COURT (Street) NOVATO CA 94949 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol Ultragenyx Pharmaceutical Inc. [ RARE ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner X Officer (give title below) Other (specify below) President & CEO
	3. Date of Earliest Transaction (Month/Day/Year) 02/05/2014
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/05/2014		C		624,240	A	(1)	624,240	D
Common Stock								2,552,241	I	By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 2009

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series A Preferred Stock	(1)	02/05/2014		C			1,956,686	(1)	(1)	Common Stock	624,240(2)	$0.00	0	D
Warrant to Purchase Series A Preferred Stock (Right to Buy)	$0.959	02/05/2014		J			260,688(3)	06/16/2011	06/30/2020	Series A Preferred Stock	260,688	$0.00	0	D
Warrant to Purchase Common Stock (Right to Buy)	$3.01	02/05/2014		J		83,039(3)		06/11/2011	06/30/2020	Common Stock	83,039	$0.00	0	D
Warrant to Purchase Series A Preferred Stock (Right to Buy)	$0.959	02/05/2014		J			78.206(3)	06/16/2011	06/14/2021	Series A Preferred Stock	78,206	$0.00	0	D
Warrant to Purchase Common Stock (Right to Buy)	$3.01	02/05/2014		J		24,950(3)		06/16/2011	06/14/2021	Common Stock	24,950	$0.00	0	D
Warrant to Purchase Series A Preferred Stock (Right to Buy)	$0.959	02/05/2014		J			130,344(3)	06/16/2011	06/14/2021	Series A Preferred Stock	130,344	$0.00	0	D
Warrant to Purchase Common Stock (Right to Buy)	$3.01	02/05/2014		J		41,583(3)		06/16/2011	06/14/2021	Common Stock	41,583	$0.00	0	D

Explanation of Responses:

1. The Series A Convertible Preferred Stock converted into the Issuer's common stock on a 1 for 3.1345 basis, such that every 3.1345 shares of Series A Convertible Preferred Stock converted into one share of common stock, and had no expiration date.

2. Reflects a 1-for-3.1345 reverse stock split which became effective on January 17, 2014.

3. Immediately prior to the closing of the Issuer's initial public offering, this warrant to purchase shares of Series A Preferred Stock automatically converted on a 1-for-3.1345 basis into a warrant to purchase shares of Common Stock. Disposition of Warrant to Purchase Series A Preferred Stock and acquisition of Warrant to Purchase Common Stock listed solely for the purpose of reporting such conversion of the shares underlying the security.

Remarks:

	By: /s/ Ryan Murr by power of attorney for Emil D. Kakkis, M.D., Ph.D.	02/06/2014
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.